Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 12/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4473633 | 0.84 | CTSK (0.49) | CASP3CTSLCTSBCTSSCTSK | |
| SCHEMBL4466585 | 0.82 | CASP3 (0.54) | CASP3CTSLCTSBCTSSCTSK | |
| SCHEMBL13914077 | 0.82 | CASP3 (0.54) | CASP3CTSLCTSBCTSSCTSK | |
| SCHEMBL4466886 | 0.81 | CTSK (0.58) | CTSLCTSBCTSSCTSK | |
| SCHEMBL4460239 | 0.80 | MEN1 (0.57) | CASP3CYP3A4CTSLCTSBCTSS | |
| SCHEMBL13914073 | 0.78 | CTSK (0.48) | CYP3A4TSHRCTSLCTSBCTSS | |
| SCHEMBL13914075 | 0.78 | FOLH1 (0.54) | CTSLCTSBCTSSCTSKFOLH1 | |
| SCHEMBL8447913 | 0.78 | FOLH1 (0.54) | CTSLCTSBCTSSCTSKFOLH1 | |
| SCHEMBL4467248 | 0.78 | CTSK (0.54) | CASP3CTSLCTSBCTSSCTSK | |
| SCHEMBL31377319 | 0.76 | MAPT (0.49) | CYP3A4TSHRFOLH1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504382-B2 | Protease inhibitors for coronaviruses and SARS-CoV and the use thereof | CYTOVIA, INC. (US) | 2009-03-17 | — | — | US | claimed |
| US-20080300191-A1 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | CYTOVIA, INC. | 2008-12-04 | — | — | US | claimed |
| EP-1628674-A2 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | Cytovia, Inc. (US) | 2006-03-01 | — | — | EP | claimed |
| WO-2004101742-A2 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | CYTOVIA, INC (US) | 2004-11-25 | — | — | WO | claimed |
| US-7504382-B2 | Protease inhibitors for coronaviruses and SARS-CoV and the use thereof | CYTOVIA, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080300191-A1 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | CYTOVIA, INC. | 2008-12-04 | — | — | US | disclosed |
| EP-1628674-A2 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | Cytovia, Inc. (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004101742-A2 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | CYTOVIA, INC (US) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300191-A1 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | ACE, ACE2, TMPRSS2 | CASP3 200/4885CYP3A4 1645/4885TSHR 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.